Archives
-
o2h Ventures Announces SEIS Investment in Innovative mRNA-Based Hearing Loss Treatment Company, CamGene Therapeutics
05 April, 2024
-
o2h Ventures ‘WINS’ Runner Up for ‘Best EIS Manager – Specialist’ at Growth Investor Awards 2023
25 November, 2023
-
ViaNautis (formerly Somaserve) secured a $25M Series A round with a follow-on investment from o2h Ventures.
13 November, 2023
-
o2h Ventures continues to back Pencil Biosciences in its £5.6M Seed investment
29 September, 2023
-
o2h Ventures qualified as a finalist as Best EIS Manager – Specialist at Growth Investor Awards 2023
14 August, 2023
-
o2h Ventures selected as finalist for best seed VC in UKBAA awards 2023
14 June, 2023
-
o2h Ventures recognized as a finalist for the EISA Impact Award for 2023
08 June, 2023
-
PharmEnable raises $7.5M in Pre-Series A funding round with a follow-on investment from o2h Ventures
29 May, 2023
-
Tay Therapeutics, an o2h Ventures portfolio company secures a licensing deal worth over $65 million
05 May, 2023